Research programme: KRAS G12C protein inhibitors - Erasca
Alternative Names: ERAS-1Latest Information Update: 02 Sep 2021
At a glance
- Originator The Regents of the University of California
- Developer Erasca
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Sep 2021 Preclinical trials in Solid tumours in USA (unspecified route) prior to September 2021 (Erasca pipeline, September 2021)
- 01 Sep 2021 Erasca plans IND-enabling studies for Solid tumours in USA in the second half of 2021
- 01 Sep 2021 Early research in Solid tumours in USA (unspecified route) prior to September 2021 (Erasca pipeline, September 2021)